Immunodermatology News

Childhood BMI was significantly associated with hidradenitis suppurativa development in adulthood, according to a study published in JAMA Dermatology.

Ixekizumab may reduce signs and symptoms of pityriasis rubra pilaris in some patients.

Infliximab maintenance therapy could reduce pain and disease activity in hidradenitis suppurativa, according to a study published in Journal of the American Academy of Dermatology.

Biologics were more likely to improve psoriasis than methotrexate in pediatric patients, as assessed by both the Psoriasis Area and Severity Index and Physician Global Assessment, according to a study.

Patients with cutaneous immune-mediated diseases, such as psoriasis, atopic dermatitis and hidradenitis suppurativa, may not have an increased risk for developing severe COVID-19, based on available data from the current and previous coronavirus outbreaks.

Standard of care treatments for morphea yielded reasonable success over long-term follow-up, according to a study.

MRI may be more sensitive in detecting morphea disease activity than clinical assessment, according to a research letter.

A retrospective analysis showed that patients with recalcitrant morphea benefited from mycophenolate therapy, with tolerable adverse events.

Initial score on the Pemphigus Disease Area Index and evolution of anti-desmoglein antibody values 3 months after an initial cycle of rituximab are associated with short-term pemphigus relapse, according to a post hoc analysis of a randomized clinical trial published in JAMA Dermatology.

Despite their much-touted potential to drastically lower the cost of pricey biologics and improve care for patients across a spectrum of diseases, biosimilars have been slow to take root across the country, particularly in comparison with Europe.